

Different Mutant/Wild-Type *p53* Combinations Cause a Spectrum of Increased Invasive Potential in Nonmalignant Immortalized Human Mammary Epithelial Cells¹

Damian J. Junk^{*,†}, Lukas Vrba[†], George S. Watts^{†,‡},
Marc M. Oshiro[†], Jesse D. Martinez^{*,†,§}
and Bernard W. Futscher^{*,†,¶}

*Cancer Biology Graduate Interdisciplinary Program, The University of Arizona, Tucson, AZ 85724, USA; [†]Arizona Cancer Center, The University of Arizona, Tucson, AZ 85724, USA; [‡]Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ 85724, USA; [§]Department of Cell Biology and Anatomy, The University of Arizona, Tucson, AZ 85724, USA; [¶]Department of Pharmacology & Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85724, USA

Abstract

Aberrations of *p53* occur in most, if not all, human cancers. In breast cancer, *p53* mutation is the most common genetic defect related to a single gene. Immortalized human mammary epithelial cells resemble the earliest forms of aberrant breast tissue growth but do not express many malignancy-associated phenotypes. We created a model of human mammary epithelial tumorigenesis by infecting hTERT-HME1 immortalized human mammary epithelial cells expressing wild-type *p53* with four different mutant *p53* constructs to determine the role of *p53* mutation on the evolution of tumor phenotypes. We demonstrate that different mutant/wild-type *p53* heterozygous models generate loss of function, dominant negative activity, and a spectrum of gain of function activities that induce varying degrees of invasive potential. We suggest that this model can be used to elucidate changes that occur in early stages of human mammary epithelial tumorigenesis. These changes may constitute novel biomarkers or reveal novel treatment modalities that could inhibit progression from primary to metastatic breast disease.

Neoplasia (2008) 10, 450–461

Introduction

Inactivation of the tumor suppressor gene *p53* occurs in most human cancers [1]. In breast cancer, loss of one *p53* allele occurs in 47% to

64% of tumor tissues with no evidence of homozygous deletion and no significant correlation with mutation of the remaining allele [2–5]. Mutation of the *p53* gene occurs in 15% to 30% of breast cancers,

Abbreviations: *APAF1*, apoptotic peptidase activating factor 1; *CDH11*, cadherin 11; *ChIP*, chromatin immunoprecipitation; *CSPG2*, versican; *E2F5*, E2F transcription factor 5; *FAS*, TNF receptor superfamily member 6; *GAPDH*, glyceraldehyde-3-phosphate dehydrogenase; *GFP*, green fluorescent protein; *HME1*, hTERT-immortalized human mammary epithelial cells; *HMEC*, human mammary epithelial cells; *MASPIN*, mammary serine protease inhibitor; *MDM2*, mouse double minute; *p21*, cyclin-dependent kinase inhibitor 1A; *PIG11*, *p53*-induced gene 11; *PIG12*, *p53*-induced gene 12; *PLK3*, Polo-like kinase 3; *POLH*, polymerase (DNA-directed) eta; *STAU-2*, staufen RNA binding protein homolog 2; *TFPI2*, tissue factor pathway inhibitor 2; *TP53I3*, *p53*-inducible protein 3; *TP53INP1*, *p53*-inducible nuclear protein 1; *TP53TGI*, *p53* target gene 1; *WIG1*, wild-type *p53*-induced gene 1

Address all correspondence to: Dr. Bernard W. Futscher, Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ 85724-5024. E-mail: bfutscher@azcc.arizona.edu

¹We thank Bert Vogelstein for the control and *p53* adenoviruses. We thank Douglas W. Cromey, M.S. of the Department of Cell Biology & Anatomy and the Southwest Environmental Health Sciences Center/National Institute of Environmental Health Sciences (NIEHS) grant ES06694 for microscopy. We thank José Muñoz-Rodríguez for generating microarray data at the University of Arizona Genomics Shared Service supported by NIEHS grant ES06694, National Institutes of Health (NIH) grant CA23074, and the Bio-5 Institute. D.J. J. was supported in part by a Cancer Biology Training grant CA09213 and an Integrative Graduate Education and Research Traineeship grant NSF DGE 0114420. B.W. F. was supported by NIH grant CA65662. The Arizona Cancer Center also supported this work.

Received 7 January 2008; Revised 11 February 2008; Accepted 15 February 2008

making this the most common genetic defect related to a single gene [6–9]. Mutation of *p53* causes accumulation of the protein that can be detected in tissue by immunohistochemistry [4]. Because the mutant *p53* protein is retained and accumulated, it has been hypothesized that it plays a functional role in tumorigenesis.

The role of *p53* mutation has often been analyzed in malignantly transformed cancer cell lines that are *p53* wild-type or *p53* null. These studies have shown that DNA binding domain mutations of *p53* produce three possible consequences: loss of wild-type *p53* function, dominant negative activity, and gain of function. Mutant *p53* was shown to bind DNA less efficiently than wild-type *p53*, demonstrating a loss of function phenotype [10,11]. Coinfection studies of wild-type and mutant *p53* in a *p53* null background showed reduced expression of wild-type *p53* target genes, which was linked to a concomitant decrease in DNA binding demonstrating a dominant negative activity [12]. Gain of function for mutant *p53* was demonstrated in *p53* null cancer cell lines through increased growth in soft agar and tumorigenicity in mouse xenografts, which were likely due in part to changes in gene expression caused by the mutant *p53* protein [13–19].

Two recent studies have examined the effect of *p53* mutant/wild-type heterozygosity on tumor development in mice [20,21]. Knock-in of two mutant *p53* alleles, R172H or R270H, in a wild-type *p53* background demonstrated specific accumulation of *p53* in tumor tissues that did not occur in surrounding normal tissue. Loss of the remaining wild-type *p53* allele did occur but was not universal among all tumor types. Although the mutant *p53* knock-in mice displayed similar tumor development and organism survival rates to *p53* heterozygous knockout mice, there was an increase in osteosarcomas, premalignant epithelial lesions, and carcinomas in response to the mutant *p53*. Finally, the osteosarcomas and epithelial tumors of these mice were locally invasive or frequently metastasized compared to the *p53* heterozygous knockout mice, which completely lacked metastases. Thus, mutant *p53* specifically accumulated in tumor tissues, and accumulation was associated with the development of a metastatic phenotype often, despite the presence of a functional wild-type *p53* allele.

In the present study, we extend these findings to human mammary epithelial cells (HMEC) by the introduction of four mutant *p53* proteins (R175H, R273H, R280K, and R249S) into wild-type *p53*, hTERT-immortalized HMEC, hTERT-HME1 (HME1), using a lentiviral delivery system. Human mammary epithelial cell culture and immortalization has been studied extensively [22–24]. Ectopic expression of the *hTERT* gene can rapidly convert postselection HMEC to full immortalization [25]. Recent studies of the continuum of HMEC cultures suggest that immortalized HMEC do resemble some of the earliest forms of aberrant breast tissue growth, but they do not display malignant phenotypes [26]. Culture models suggest that addition of oncogenes such as *ZNF217* and activated *RAS* confer many of the malignancy-associated phenotypes missing in immortalized HMEC [27,28]. Similarly, we used this cell culture model to analyze the effect of mutant/wild-type *p53* heterozygosity on malignant phenotypes.

We show that accumulation of exogenous mutant *p53* is accompanied by an equivalent increase in wild-type *p53* in the HME1 cells. We demonstrate that dominant negative activity of mutant *p53* is sufficient to inhibit wild-type *p53* binding to DNA and to alter patterns of wild-type *p53* target gene expression. Furthermore, we show that accumulation of each mutant *p53* results in unique changes in gene expression and a spectrum of increased invasive potential of these cells. The results of our model system agree with previously

described functional consequences of *p53* mutation and extend the increased invasiveness and metastatic potential of *p53* mutant/wild-type heterozygous status to human mammary epithelial cells. This model will be useful for determining how *p53* mutation drives the progression of a noninvasive primary tumor to metastatic breast cancer in humans.

Materials and Methods

Cell Culture and Doxorubicin Treatment

The cell lines hTERT-HME1, MDA-MB-468, MDA-MB-231, and BT549 were purchased from the American Type Culture Collection (Rockville, MD). 293FT cells were purchased from Invitrogen (Carlsbad, CA). The hTERT-HME1 cells were grown in mammary epithelial cell growth medium (Cell Applications, San Diego, CA). 293FT cells were grown according to Invitrogen's protocols. The others were cultured as previously described [29]. Doxorubicin (Sigma-Aldrich, St. Louis, MO) was added for 18 hours to the cell culture media at a final concentration of 500 nM.

Adenoviral Infections

Adenovirus containing wild-type *p53* with GFP, R175H mutant *p53* with GFP, or with GFP alone was the kind gift of Bert Vogelstein and was propagated as previously described [29]. Adenovirus was added to the growth media at 100 plaque-forming units per cell for 24 hours.

Nucleic Acid Isolation

Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA). Genomic DNA was isolated using a DNeasy Blood and Tissue Kit (Qiagen).

Mutant *p53* Cloning

Four mutant *p53* sequences were isolated from MDA-MB-231 (R280K), MDA-MB-468 (R273H), BT549 (R249S) or the R175H adenovirus. Extensive genomic sequencing analysis of MDA-MB-231 cells conducted by our laboratory show they express only mutant *p53* R280K. According to the International Agency for Research on Cancer mutant *p53* database, the MDA-MB-468 cells lost the wild-type allele and expressed only mutant *p53* R273H. BT549 harbors the mutant *p53* R249S, and the status of the other allele is unknown. The *p53* sequences were reverse-transcribed using a gene-specific primer and the Superscript III kit (Invitrogen). Blunt-ended polymerase chain reaction (PCR) fragments of the *p53* constructs were generated by the Platinum Pfx DNA polymerase kit (Invitrogen). Primer sequences are available on request.

Lentiviral Particle and Stable Cell Line Generation

The four mutant *p53* PCR products were cloned into the pLenti6/V5-D-Topo vector (Invitrogen). Each construct was validated for the correct *p53* mutation by DNA sequencing. Lentiviral particles were generated by individually transfecting 293FT cells with the four mutant *p53* pLenti6/V5 constructs and the ViraPower Packaging Mix with Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen). Stable mutant *p53*-expressing HME1 cells were generated by infection with lentiviral particles at a 1:100 dilution in growth media with 6 µg/ml polybrene (Sigma-Aldrich). Selection

of stably expressing mutant *p53* cell lines was conducted with 2 $\mu\text{g}/\text{ml}$ blasticidin (Invitrogen).

Immunoprecipitation and Western Blot Analyses

Protein was isolated in radio immunoprecipitation assay buffer and was quantitated by the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA). Total protein (1 mg) was precleared. A total of 2 μg of α -V5 (Invitrogen) or IgG2a isotype control antibody (Calbiochem, San Diego, CA) was added and rotated overnight at 4°C. Protein A/G beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were added to each sample for 1 hour, and beads were washed four times in radio immunoprecipitation assay buffer and twice in phosphate-buffered saline (PBS). Immunoprecipitates or 30 μg of total protein lysates was loaded into 7.5% Tris-HCl Ready Gels (Bio-Rad Laboratories), except the V5 Western blot in Figure 1, which was loaded into 10% Tris-HCl Ready Gels (Bio-Rad Laboratories). Blots were incubated with either α -V5 HRP-conjugated antibody (Invitrogen) or α -*p53* HRP-conjugated antibody clone DO-1 (Santa Cruz Biotechnology, Inc.) and α -actin clone AC40 (Sigma-Aldrich). For actin, a goat anti-mouse HRP secondary antibody (Santa Cruz Biotechnology, Inc.) was used for detection. Blots were incubated with ECL Western Blotting Detection Reagents (Amersham Biosciences, Piscataway, NJ) and were exposed to BioMax XAR film (Kodak, Rochester, NY). Western blots from three independent immunoprecipitations were captured and quantitated using the Gel Logic 200 Imaging System and associated software (1D v3.6.4; Kodak).

Subcellular Localization of *p53*

Cells grown on coverslips were fixed with 4% paraformaldehyde in PBS, permeabilized with 0.2% Triton X-100, and blocked with 5% BSA. Fixed cells were incubated for 1 hour with α -*p53* primary antibody AB-6 clone DO-1 (Calbiochem). Cells were then stained for 1 hour with anti-mouse IgG Cy3 secondary antibody (Sigma-Aldrich). Nuclei were visualized with 4',6-diamidino-2-phenylindole (Molecular Probes, Inc., Eugene, OR). Coverslips were mounted on glass slides, and stained cells were analyzed using fluorescent microscopy.

Real-Time Reverse Transcription-Polymerase Chain Reaction

Real-time reverse transcription-polymerase chain reaction (RT-PCR) was conducted for *WIG1*, *p21*, *MDM2*, and *GAPDH* according to the Applied Biosystems (Foster City, CA) protocol as previously described [29]. For *TP53I3*, *STAU-2*, *E2F5*, *CDH11*, *TFPI2*, and β -*actin*, primers were designed for use with the Human Universal Probe Library Set (Roche Diagnostics, Indianapolis, IN) and conducted on an ABI Prism 7000 Sequence Detection System (Applied Biosystems) with a 95°C denaturation for 3 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 45 seconds. All experiments were conducted in triplicate from three independent RNA isolations. Primer sequences are available on request.

13k Human Promoter Microarray

Primers were obtained from the Whitehead Institute [30]. Microarray probes were generated from a pooled sample of human mononuclear genomic DNA by PCR (ABgene, Rochester, NY). Products were analyzed by the E-Gel 96 system (Invitrogen), purified using the QIAquick 96 PCR Purification Kit (Qiagen), and quantified using the ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE). DNA was lyophilized and resuspended in 10 μl

of 3 \times SSC for printing onto Ultra GAPS slides (Corning, Lowell, MA) using an OmniGrid robot (GeneMachines, San Carlos, CA). Slides were hydrated and UV cross-linked. Slides were preincubated with 1% BSA, 4 \times SSC, 0.5% SDS at 42°C, followed by incubation in 1% SDS, 0.25% sodium borohydride at 42°C. Slides were washed in 0.06 \times SSC, 0.1% SDS, then in 0.06 \times SSC, and then in double-distilled water.

Microarray Detection of *p53* Binding

p53-Specific chromatin immunoprecipitation (ChIP) was performed using antibody clone DO-1 (AB-6; Calbiochem) as previously described, except that the final purification was done using a QIAquick PCR purification kit (Qiagen) [31]. Immunoprecipitated DNA was quantified using PicoGreen dye (Invitrogen). Equal amounts of ChIP and input DNA were amplified using the BioPrime DNA Labeling System (Invitrogen). Second-round amplification was conducted with Cy3 and Cy5 dyes for labeling (GE healthcare, Piscataway, NJ). Labeled DNA was purified using a QIAquick PCR purification kit (Qiagen). Labeled targets were mixed with 20 μg of human Cot-1 DNA (Invitrogen) and 40 μg of yeast tRNA (Invitrogen), dried under vacuum, dissolved in Domino Oligo Hybridization Buffer DMH-25 (Gel Company, San Francisco, CA), and denatured. Samples were hybridized to processed slides in an ArrayBooster (Advantix AG, Concord, MA) at 42°C for 16 hours. Hybridized slides were washed in 2 \times SSC, 0.1% SDS, then 0.06 \times SSC, 0.1% SDS, and finally 0.06 \times SSC. Slides were scanned using an Axon GenePix 4000 (Axon Instruments, Inc., Foster City, CA). Experiments were done in triplicate using dye swap resulting in six slides per cell line. The data were analyzed using limma package for R [32]. Arrays were normalized using loess function for within array normalization and quantile function for between array normalization. A linear model fit was calculated using input as a common reference. The elements referred to as bound by *p53* within this paper were enriched in cell treatments over parental at P value $\leq .01$.

Real-Time PCR Verification of ChIP-Chip Analysis

p53-Specific ChIP was performed as described for the microarray in previous paragraphs. Immunoprecipitated DNA was quantified using PicoGreen dye (Invitrogen) and a BioTek FLx800 Multi-Detection Microplate Reader (BioTek Instruments, Winooski, VT). Equal amounts (100 pg) of ChIP and input DNA were used for real-time PCR analysis. Enrichment was calculated as previously described [31]. Primer sequences are available on request. Mutant *p53* inhibited binding to an extent that very little DNA was yielded compared to the wild-type *p53* infection. The yield from the mutant *p53* cell lines was so miniscule it was not possible to assay them with this real-time PCR method.

Microarray Expression Analysis

Total RNA was processed according to the protocol recommended by Affymetrix (Santa Clara, CA). In all, 20 μg of labeled cRNA from each sample was hybridized to the GeneChip Human Genome U133A Plus 2.0 Array (Affymetrix). The expression data were analyzed using GeneSpring GX 7.3.1 (Agilent Technologies, Santa Clara, CA). Data were normalized per chip to the 50th percentile then to the hTERT-HME1 reference cell lines (HME1 parental, vector only lentivirally infected, and GFP adenovirally infected). Gene lists were generated using a two-fold cutoff for both of two replicates

of each *p53* treatment studied compared to the GFP cell lines for wild-type *p53* and vector only for mutant *p53*.

Flow Cytometry

Parental HME1, vector only control, mutant *p53*-expressing cell lines, adenoviral GFP, and wild-type *p53*-infected cells were analyzed in duplicate by flow cytometry. For serum deprivation experiments, parental HME1, vector only control, and mutant *p53*-expressing cell lines were exposed to basal growth media for 24 hours then subjected to flow cytometry analysis in duplicate. Cells were harvested, washed, and incubated overnight with 95% ethanol. Cells were pelleted and resuspended in PBS, treated with RNase A, and stained with propidium iodide (Sigma-Aldrich). Flow cytometric analysis was performed using a FACScan flow cytometer (BD Biosciences, San Jose, CA) equipped with an air-cooled 15-mW argon ion laser tuned to 488 nm. List mode data files consisting of 10,000 events gated on forward scatter *versus* side scatter were acquired and analyzed using CellQuest PRO software (BD Biosciences) at a rate of 200 to 400 events per second. Curve fit analysis was prepared using ModFit LT version 3.1 (BD Biosciences).

Cell Proliferation Assay

HME1, vector only, and mutant *p53*-expressing cells were counted on a Vi-CELL (Beckman Coulter, Inc., Fullerton, CA), and 60,000 cells were plated in T-25 flasks in triplicate at day 0. Cells were counted on a Vi-CELL (Beckman Coulter, Inc.) at days 1, 3, and 5 in triplicate.

Clonogenic Assay

HME1, vector only, and mutant *p53*-expressing cells were counted on a Vi-CELL (Beckman Coulter, Inc.) and were plated in triplicate at 125, 63, and 31 cells/well dilutions. The cells were grown for 2 weeks and were stained with 500 μ l of 0.5% crystal violet in 20% methanol. Colonies were counted manually in triplicate.

Anchorage-Independent Growth

HME1, vector only, mutant *p53*-expressing cells, and MDA-MB-231 cells were counted on a Vi-CELL (Beckman Coulter, Inc.). A total of 5000 cells were grown in semisolid media consisting of 0.2% agar noble (BD Biosciences) in triplicate for 3 weeks. Cells were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich) and were counted in triplicate.

Migration and Invasion Assays

Cells were counted on a Vi-CELL (Beckman Coulter, Inc.) and plated in both uncoated and BD BioCoat growth factor-reduced matrigel chambers (BD Biosciences) in quadruplicate for each cell line. A total of 50,000 cells were placed in each chamber and incubated for 48 hours. For the wild-type *p53* and GFP control, adenovirus was added 24 hours before counting and plating. The chambers were stained with 50 μ l of 0.5% crystal violet in 20% methanol for 1 minute then swabbed on the inside to remove noninvasive cells, washed twice in distilled water, and quantitated. Images of 14 fields, representing 85% of the total surface area, were captured using a \times 10 objective with a \times 1.5 optivar on an Olympus IMT-2 microscope (Olympus America Inc., Center Valley, PA), a Hamamatsu ORCA-100 grayscale CCD camera (Hamamatsu USA, Bridgewater, NJ), and a Ludl motorized XY stage (Ludl Electronic Products, Hawthorne,

NY). SimplePCI software version 6.2 (Compix, Inc., Sewickley, PA) controlled the camera and stage, created a binary image, and measured the image for the area. Significance was measured with a one-sided Student's *t* test comparing vector control and each mutant treatment to the parental cell line.

Results

Generation of Human Mammary Epithelial Model of Tumorigenesis

Four human mutant *p53* cDNAs R175H, R273H, R280K, and R249S were cloned, sequence-validated, and packaged as lentiviral particles. These mutations represent the most common point mutations of *p53* in breast tissue. Stable HME1 cell lines expressing vector only or cytomegalovirus promoter-driven mutant *p53* were created by lentiviral infection and blasticidin selection. The transduced mutant *p53* constructs were V5 epitope-tagged to discriminate between exogenous mutant *p53* and endogenous wild-type *p53* protein in the HME1 cells.

Stably Expressed Mutant *p53* Causes Accumulation of the Endogenous Wild-Type Protein

Western blot demonstrated that HME1 parental cells express low but detectable levels of wild-type *p53*, and control viral infections did not alter this level (Figure 1A). *p53* levels in parental HME1 cells increased with doxorubicin treatment, indicating that the endogenous wild-type *p53* response is functional (Figure 1A). In addition, mutant *p53* accumulated in the transduced HME1 cell lines (Figure 1, A and C, *top bands*). As expected, no proteins were detected in the HME1, DOX, GFP, and Vector cell lines using the anti-V5 antibody (Figure 1B). The levels of exogenous V5-tagged mutant *p53* protein were variable in the HME1 cell lines (Figure 1B). The R273H and R280K mutant protein levels were about 1.5 times higher than the R175H and R249S. The endogenous wild-type *p53* protein in the same cells was also accumulated (Figure 1, A and C, *bottom bands*). Infection with a wild-type *p53* adenovirus produced accumulation of the protein to a similar level seen in the mutant *p53* stably infected HME1 cell lines (Figure 1C). In the *p53* heterozygous HME1 cell lines, mutant *p53* accumulates to similar levels as the mutant protein in three breast cancer cell lines (Figure 1C). Taken together, the stable HME1 cell lines highly accumulate mutant *p53* to a level seen in breast cancer cell lines, and in response to the mutant protein accumulation, the endogenous wild-type *p53* accumulates to a level that can be recapitulated by adenoviral infection of wild-type *p53* alone.

Exogenous Mutant and Endogenous Wild-Type *p53* Protein Interact

We immunoprecipitated mutant *p53* from cell lysates with an antibody against the V5 tag to examine *p53* interactions in the HME1 cells. The protein complexes were separated by SDS-PAGE and were probed with *p53* antibody. Mutant *p53*-infected cells revealed an interaction between the exogenous mutant and endogenous wild-type *p53* proteins (Figure 2A). Quantification demonstrated equal amounts of mutant and wild-type *p53* protein in each immunocomplex, suggesting that they bound in a stoichiometric manner (Figure 2B, compare mut to w.t. for each mutant cell line).




Figure 1. Endogenous wild-type p53 accumulates in response to mutant p53 accumulation. Western blots were conducted with either anti-V5 or anti-p53 clone DO-1 and anti-actin as a loading control. (A) One representative Western blot from three independent experiments shows p53 levels in parental (HME1), doxorubicin-treated (DOX), GFP only control (GFP), vector only control (Vector), and mutant p53-expressing HME1 cell lines (R175H, R273H, R280K, and R249S). The double band for p53 in lanes 5 to 8 represents the exogenous V5-tagged mutant p53 as the larger protein and the endogenous wild-type p53 as the smaller protein. (B) One representative Western blot from three independent experiments demonstrates the relative accumulation of the V5-tagged exogenous mutant p53 in each of the mutant p53-expressing HME1 cell lines; labels are the same as panel A. (C) One representative Western blot from three independent experiments of adenoviral wild-type p53 (Ad w.t. p53), mutant p53-expressing HME1 stable cell lines (R175H, R273H, R280K, and R249S), MDA-MB-468, MDA-MB-231, and BT549 breast cancer cell lines. The double band for p53 in lanes 2 to 5 represents the exogenous V5-tagged mutant p53 and the endogenous wild-type p53.

We examined subcellular localization of mutant and wild-type p53. Results showed that mutant and wild-type p53 enter the nucleus in each cell line tested (Figure 3). Taken together, these data show the mutant p53 proteins are not defective either in tetramerization or in nuclear trafficking.

Microarray Expression Analysis Supports the Dominant Negative Activity of Mutant p53

We conducted microarray expression analyses to determine the effect of mutant p53 accumulation on gene expression in HME1 cells. Because wild-type p53 was accumulated in the heterozygous mutant/wild-type p53 HME1 cell lines, HME1 parental cells were also transiently infected with wild-type p53 adenoviruses to produce a comparable level of p53 protein and induce a wild-type-only response [33]. We then compared gene expression changes between wild-type

p53 only, and mutant/wild-type p53-expressing HME1 cells. Two independent RNA samples from adenoviral wild-type p53 and the four lentiviral mutant p53-infected cell lines were hybridized to the GeneChip Human Genome U133A Plus 2.0 Array (Affymetrix). Genes were selected as up or down regulated by filtering for genes that showed a two-fold change in both of the duplicate hybridizations relative to the GFP only control for wild-type and vector only control for mutant/wild-type p53-expressing cell lines. Entire gene lists are available on request.

Induction of wild-type p53 from adenoviral infection of HME1 cells caused an increase in the expression of 599 genes (Table 1), including known p53 targets such as *p21*, *MDM2*, *WIG1*, *TP53I3*, *TP53I5*, *TP73*, *TP53INP1*, *CSPG2*, *PIG11*, *PIG12*, *TP53TG1*, *POLH*, *PCAF*, *MASPIN*, and *APAF1*. Wild-type p53 also caused a reduction in the expression of 748 genes (Table 1), such as *FEN1*, *PFS2*, *CSPG6*, *CDC2*, *MCM2*, *MCM6*, *MCM7*, *MSH2*, and *MSH6*, which has been previously demonstrated [34].

Although there is an equivalent level of wild-type p53 in adenoviral-infected and mutant p53 lentiviral-infected HME1 cells (Figure 1C), mutant p53 blocked changes in expression of the majority of wild-type p53 target genes. Only a small fraction (3.6% to 6.7%) of the genes affected by wild-type p53 was also targeted in the mutant/wild-type p53 HME1 cell lines (Table 1). Real-time RT-PCR confirmed the




Figure 2. Endogenous wild-type p53 interacts with accumulated exogenous mutant p53. Immunoprecipitations were conducted with a non-specific antibody, or an anti-V5 antibody that recognizes the exogenous mutant p53 protein. Western blots of the immunoprecipitates were conducted with an anti-p53 clone DO-1 antibody that recognizes both mutant and wild-type p53. (A) One representative Western blot from three independently immunoprecipitated samples. Lane 1 is 30 μ g of whole cell lysate (WCL) from HME1 as a positive control for p53. Even lanes 2 to 14 are immunoprecipitates of the nonspecific antibody control. Odd lanes 3 to 15 are V5 antibody-specific immunoprecipitates. (B) Levels of wild-type p53 relative to the mutants in each HME1 mutant p53-expressing cell line. The quantification and standard error of the mean were calculated from Western blots of three independent experiments and show the amounts of wild-type p53 (w.t.) relative to the mutant p53 (mut) in each of the HME1 mutant p53-expressing cell lines (R175H, R273H, R280K, and R249S).




Figure 3. Mutant *p53* does not inhibit nuclear localization of wild-type *p53* in HME1 cells. Parental (HME1), vector only control (Vector), and mutant *p53* (R175H, R273H, R280K, and R249S) stably expressing HME1 cells were assayed by immunofluorescence for subcellular localization of *p53*. Cells were stained for *p53* with Cy3 (top row, red). Nuclei were counterstained with 4',6-diamidino-2-phenylindole (middle row, blue). Images were merged to show nuclear localization of *p53* in all cell lines (bottom row, pink).

microarray results for the induction of *p21*, *MDM2*, *TP53I3*, and *WIG1* by wild-type *p53*, and the ability of mutant *p53* to block their induction (Figure 4). The gene expression results demonstrated induction of wild-type *p53* target genes in cells in response to wild-type *p53* alone, but not in cells expressing wild-type and mutant *p53*. Thus, these data confirm that mutant *p53* induces a dominant negative effect on wild-type *p53* resulting in a lack of responsiveness of wild-type *p53* target genes.

Chromatin Immunoprecipitation Analysis Confirms the Dominant Negative Activity of Mutant *p53*

We used chromatin immunoprecipitation (ChIP) coupled to a human promoter microarray to determine genome-wide DNA binding of *p53* in our cell lines. DNA-protein complexes were immunoprecipitated with *p53* antibody, and then DNA was recovered, fluorescently labeled, and hybridized to a 13,000-element human promoter array. We found that 324 gene promoters were bound by *p53* after infection with wild-type *p53* adenovirus (Figure 5A). Of these, well-described *p53* target genes *PCNA*, *FAS*, *PLK3*, *TP53INP1*, *CSPG2*, *PIG11*, *PIG12*, *TP53TG1*, *POLH*, *MASPIN*, and *APAF1* were identified. The gene expression microarray analysis for wild-type *p53* confirmed that *TP53INP1*, *CSPG2*, *PIG11*, *PIG12*, *TP53TG1*, *POLH*, *MASPIN*, and *APAF1* promoter binding resulted in increased expression.

Table 1. Wild-Type *p53* Target Gene Changes in Mutant *p53*-Expressing Cells Compared to Wild-Type *p53* Response.

	Wild-Type Changes	Similarity to Wild-Type, <i>n</i> (%)			
		R175H	R273H	R280K	R249S
Up	599	24 (4.0)	33 (5.5)	22 (3.7)	19 (3.2)
Down	748	46 (6.1)	67 (9.0)	26 (3.5)	29 (3.9)
Total	1347	70 (5.2)	90 (6.7)	48 (3.6)	48 (3.6)

The total number of gene changes in HME1 cells in response to wild-type *p53* is represented on the left. Similar gene changes in the mutant *p53*-expressing HME1 cells are presented under each mutation. The percentage of the similar changes relative to wild-type *p53* induction is presented in parentheses. The bottom line shows the overall total of up and down gene changes.




Figure 4. Real-time RT-PCR confirms dominant negative activity of mutant *p53*. The bar graphs represent average fold change in expression and standard error of the mean relative to parental HME1 cells for the vector only control, GFP control, wild-type adenoviral *p53* (Ad w.t. *p53*), and the mutant *p53*-expressing HME1 cell lines (R175H, R273H, R280K, and R249S).




Figure 5. Mutant p53 inhibits DNA binding of endogenous wild-type p53. (A) Chromatin immunoprecipitation of p53 coupled to a human gene promoter microarray was used to determine p53 binding throughout the genome. Data were analyzed from three independent experiments plus dye swap. The bar graph represents the number of elements bound by p53 in adenoviral wild-type p53-infected HME1 cells (Ad w.t. p53) and the mutant p53-expressing HME1 cells (R175H, R273H, R280K, and R249S) compared to the parental HME1 cells. Differentially bound promoters were determined as explained in materials and methods. (B) Real-time PCR confirms binding of adenoviral wild-type p53 to its target genes. The bar graph represents the fold enrichment over input of the six genes in response to adenoviral wild-type p53 infection. *GAPDH* is a control that is not bound by p53, as evidenced by no enrichment of ChIP versus input. The other genes confirm the ability of wild-type p53 to bind the promoter regions of these genes in hTERT-HME1 cells after wild-type p53 adenoviral infection.

ChIP coupled to real-time PCR confirmed the promoter microarray analysis. The p53 protein was found binding to the promoters of the identified genes *APAF1*, *PLK3*, *FAS*, and *MASPIN* in HME1 cells infected with wild-type p53 adenovirus (Figure 5B). *GAPDH*, a non-p53 target gene, was used as a negative control, and the known p53 target gene *p21* was used as a positive control. These data demonstrate that induced wild-type p53 resulted in specific DNA binding of wild-type p53 to the promoters of its target genes, and confirms the specificity of p53 binding determined by the promoter array hybridizations.

Each mutant p53 physically interacts with wild-type p53 and inhibits its binding to p53 target gene promoters (Figures 2A and 5A). Overall, we saw a greater than 99% reduction of DNA binding in HME1 cell lines expressing mutant and wild-type p53 (Figure 5A). Therefore, mutant p53 protein accumulation is sufficient to block

specific wild-type p53-DNA interactions. These data explain and complement the expression data, demonstrating a dominant negative activity of mutant p53.

Microarray Expression Analysis Demonstrates Gain of Function for Mutant p53

Although mutant p53 diminished the expression of wild-type p53 targets, each mutant p53 induced novel gene expression differences (Figure 6A). The total number and direction of two-fold gene expression changes induced by each mutant p53 were variable (Figure 6A). However, the trends of gene expression changes among the mutant p53-expressing cell lines were very similar (Figure 6B). Each mutant p53 caused an overlapping but unique spectrum of gene expression changes compared to each other, as has been previously reported [13,14]. *STAU2* and *E2F5* are two examples of genes upregulated in all of the mutant p53-expressing cell lines, but not in wild-type p53-induced cells. Real-time RT-PCR confirmed increases in the expression of these genes in response to mutant p53 accumulation (Figure 7). *CDH11* and *TFPI2* are two examples of genes downregulated by mutant p53, and real-time RT-PCR verified their decreased expression (Figure 7). These changes are possibly indirect effects of mutant p53 accumulation, because we did not detect p53 binding on the promoter array for any genes in response to mutant p53. These data demonstrate that even in the presence of wild-type p53, the mutant protein can induce novel gene expression changes that support a gain of function role for the mutant p53 proteins. Entire gene lists are available on request.

Mutant p53 Does Not Induce Many Malignant Properties in HME1 Cells

We conducted extensive analyses with the HME1 cells expressing mutant p53 to test the acquisition of hallmark malignant phenotypes in these cells. Flow cytometric analysis revealed that although there was more wild-type p53 in the mutant p53-expressing cell lines they were not susceptible to G1 arrest that is induced by wild-type p53 accumulation alone (Figure 8A). Additionally, in response to serum deprivation, all cell lines arrested in G1 regardless of the expression of mutant p53 (Figure 8B). Cell proliferation of HME1 cells was not affected by accumulation of mutant p53, because each cell line tested showed similar growth rates (Figure 8C). A dilution series of the HME1 cell lines also demonstrated no difference between the parental HME1 cells and cell lines with accumulated mutant p53 protein (Figure 8D). Finally, none of the HME1 cell lines grew in semisolid media, as opposed to MDA-MB-231 cells, which readily formed colonies (Figure 8E). Taken together, the mutant p53 expressed in HME1 cells did not increase cell proliferation, clonogenic potential, anchorage-independent growth, or cell cycle distribution in an untreated or serum-deprived state. These results suggest that mutant p53 when expressed with wild-type p53 in HMEC does not confer many of the properties associated with malignant transformation.

Mutant p53 Increases Migration and the Invasive Potential of hTERT-HME1 Cells

Although mutant p53 did not alter many phenotypes associated with malignant transformation, it did change the migratory and invasive potential of the HME1 cells. We conducted transwell assays to determine the migratory and invasive potential of the parental and vector control HME1 cells compared to the stably expressing mutant




Figure 6. Mutant *p53* alters patterns of gene expression in HME1 cells. Microarray expression analysis was conducted to determine gene expression changes in response to mutant *p53* accumulation in HME1 cells. (A) The bar graph represents the number of genes whose expression changed at least two-fold in response to mutant *p53*-expressing HME1 cell lines (R175H, R273H, R280K, and R249S). The top of each bar represents elements that were increased in expression. The bottom of each bar represents elements that were decreased in expression. The actual numbers of increased and decreased elements are embedded in the corresponding area of the graphs. (B) The heat map represents the trends in gene expression in response to mutant *p53*. It shows the expression levels in each mutant *p53* cell line of every gene that was found differentially expressed in at least one treatment from panel A. Red and green indicate increases and decreases in expression, respectively.

p53 HME1 cell lines. Cells expressing three of the four mutant *p53* constructs, R273H, R280K, and R249S demonstrated increased migration (Figure 9A). On uncoated transwells, the R273H-, R280K-, and R249S-expressing HME1 cells migrated three-, three-, and two-fold, respectively, more than HME1 parental cells, *P* value < .03 (Figure 9B). On matrigel-coated transwells, the R273H-, R280K-, and R249S-expressing HME1 cell lines demonstrated an eight-, five-, and five-fold increase, respectively, in invasive potential compared to the parental HME1 cells, which was statistically significant, *P* value < .02 (Figure 9C). The parental, vector control, and R175H HME1 cell lines demonstrated minimal and insignificant differences in migration and invasion (Figure 9, B and C). The differences in migration and invasive potential may be a result of the unique spectrum of gene expression differences caused by the different mutant *p53* proteins. Wild-type *p53* caused a reduction in both migration




Figure 7. Real-time RT-PCR confirms novel expression changes induced by mutant *p53*. The bar graphs represent average fold change in expression and standard error of the mean relative to parental HME1 cells for the vector only control, GFP control, wild-type adenoviral *p53* (Ad w.t. *p53*), and the mutant *p53*-expressing HME1 (R175H, R273H, R280K, and R249S) cell lines.




Figure 8. Mutant *p53* has no effect on a variety of phenotypes associated with tumor cells. (A) One representative depiction of cell cycle distribution demonstrates that the accumulation of different mutant *p53* proteins has no effect on the cell cycle. Addition of wild-type *p53* induces a G1 arrest. (B) One representative depiction of cell cycle distribution following serum deprivation demonstrates G1 arrest in all samples. Labels are the same from panel A. (C) The bar graph represents the average cell number and standard error of the mean for each cell line at the indicated days. The *y*-axis is cell number \times 100,000. (D) The bar graph represents the average number of colonies and the standard error of the mean for each cell line at the indicated cell dilutions. (E) The bar graph represents the average and standard error of the mean of colonies grown in semisolid media for each cell line. MDA-MB-231 cells were used as a positive control.

and invasion compared to the parental and GFP adenovirally infected control cells (Figure 9, A–C). This reduction likely occurs because of the cell cycle arrest and cell death induced by the accumulation of wild-type *p53* within the time frame of the assay.

Discussion

A multitude of previous studies have suggested a number of functions for mutant *p53* by expressing it in a variety of malignantly transformed cells that were *p53* null or wild-type. We have created a unique model by stably infecting nonmalignantly transformed, immortalized HMEC with mutant *p53* to determine the role of *p53* heterozygosity in tumorigenesis and malignancy acquisition. In this model, accumulation of mutant *p53* protein levels was similar to that seen in three breast cancer cell lines. Interestingly, each mutant *p53* in the cancer cell lines was slightly different in size, consistent with differences found previously [8]. The mutant *p53* consistently maintained the differences in size when expressed in the HME1 cell lines. The change in size likely reflects differing posttranslational modifications that are unique to each mutant and occur when that protein is expressed in any cell. Because we show that the mutant and wild-type *p53* proteins interact, the wild-type protein also likely receives the

same posttranslational modification as the mutant *p53* protein. Therefore, the wild-type *p53* protein is consistently different in size from the exogenous mutant by the size of the V5 tag, but among the HME1 mutant *p53*-expressing cell lines, each mutant and wild-type *p53* protein are slightly different. Interestingly, the elevated levels of mutant *p53* protein were matched by a concomitant increase in the endogenous wild-type *p53*.

We demonstrated that cellular *p53* immunocomplexes were composed of equal amounts of wild-type and mutant *p53*, consistent with earlier studies [35]. We predict that the resultant accumulation of endogenous wild-type *p53* was likely due to the stabilization induced by the interaction with the constitutively expressed exogenous mutant protein. Additionally, we demonstrated by immunofluorescence that the mutant/wild-type *p53* complexes were capable of entering the nucleus. Thus, the missense mutation in the selected mutant *p53* proteins does not inhibit tetramerization or nuclear localization.

We compared genome-wide DNA binding and gene expression profiles of the wild-type *p53*-induced and mutant *p53*-expressing HME1 cell lines. We showed that induction of wild-type *p53* alone causes binding to a multitude of promoter regions in the genome that are associated with expression changes of wild-type *p53* target genes. Mutant *p53* inhibited the ability of wild-type *p53* to bind




Figure 9. Mutant *p53* accumulation causes an increase in migration and invasiveness of hTERT-HME1 cells. Migration assays using uncoated inserts and invasion assays using matrigel-coated inserts were performed on the parental HME1 cell line (HME1), vector only control HME1 cell line (Vector), adenoviral GFP control (GFP), adenoviral infected wild-type *p53* (Ad w.t. *p53*), and mutant *p53*-expressing HME1 cell lines (R175H, R273H, R280K, and R249S). (A) Representative pictures of cells that migrated through the pores of the uncoated inserts visualized by staining with crystal violet. (B) The bar graph represents the average fold difference of migration relative to the parental HME1 cells through uncoated inserts. (C) The bar graph represents the average fold difference of invasion relative to the parental HME1 cells through matrigel-coated inserts. The cell lines were assayed in quadruplicate transwells for each experiment, and the averages were graphed with the standard error of the mean. The asterisks indicate that R273H, R280K, and R249S showed a statistically significant increase from the parental cell lines, P value < .05.

the DNA of promoters of wild-type *p53* target genes, and this inhibition was recapitulated by changes in expression of only a small percentage of wild-type *p53* target genes in the mutant/wild-type heterozygous cell lines. Therefore, the mutant *p53* protein is unable to bind DNA and blocks the ability of wild-type *p53* present in the same cells from binding the response elements of target genes and changing their level of expression. These results confirm the dominant negative activity of mutant *p53* and suggest that the accumulated endogenous wild-type *p53* is tolerated in the HME1 cells through the inhibitory effects of the exogenous mutant *p53*.

Although the ChIP analysis demonstrated that DNA binding was inhibited by mutant *p53*, each mutant *p53* in the modeled heterozygous state caused gene expression changes in the stably expressing cell lines. It is possible that these gene changes reflect interference of wild-type *p53* by each mutant, but most of the genes that are changed are not influenced by wild-type *p53*. Thus, the mutant *p53* enacts gene expression changes unique from inhibition of wild-type *p53*, and without detectable DNA binding at the relevant control regions. It is possible that the promoter array was not sensitive enough to detect mutant *p53* binding, but this is unlikely because it easily detected binding by wild-type *p53*. An alternative hypothesis is that mutant *p53* enacts gene expression changes through an indirect interaction with promoters by protein-protein interactions with other transcription factors. Indeed, previous studies have demonstrated that mutant *p53* binds the transcription factors ETS, SP1, and NF-Y influencing their activity [36–38]. The cross-linking used in this analysis was not optimized to detect this type of protein-protein-DNA interaction. These results confirm mutant *p53* gain of function demonstrated pre-

viously in *p53* null cancer cells and show that mutant *p53* gain of function can be demonstrated in a cellular background that contains wild-type *p53*.

Interestingly, we demonstrated that mutant *p53* accumulation in HME1 had no effect on cell proliferation, clonogenicity, anchorage-independent growth, or cell cycle distribution. Mutant *p53* has been shown to influence these malignant properties in other cell types and models, but often the mutant *p53* was expressed in previously transformed cells in a *p53* null background. Our data suggest that, at least in nonmalignant HMEC expressing wild-type *p53*, the mutant *p53* has no effect on these phenotypes. It may be that other defects common to malignant transformation are necessary to complement the *p53* mutation, the remaining wild-type *p53* allele must be lost to gain these additional phenotypes, or that the effects of *p53* mutation are tissue- and cell type-specific.

Although many malignant phenotypes were not acquired, we found that introduction of mutant *p53* increases the migratory and invasive potential of human mammary epithelial cells harboring wild-type *p53*. Interestingly, each mutant conferred differing levels of invasive potential from none (R175H) to high (R273H), possibly paralleling the unique gene expression changes induced by each mutant. In each mutant *p53*-expressing HME1 cell lines, the genes *TFPI-2*, *TPM1*, and *CLCA2* were downregulated. In pancreatic ductal adenocarcinomas, the *TFPI-2* gene is silenced by epigenetic inactivation, and reexpression of the gene in Panc1 cells reduces migration and invasion [39]. *TPM1* gene expression was previously found reduced in MDA-MB-231 cells in response to cytosine methylation, and reexpression of the gene reduced migration in the MDA-MB-231 cells [40]. *CLCA2*

expression is lost in malignant MDA-MB-231 and MDA-MB-468 cells, and reintroduction of this gene in MDA-MB-231 cells reduces *in vitro* matrigel invasion and metastatic tumors in nude mice [41]. Because these genes were downregulated in all of the mutant *p53*-expressing cell lines, they cannot fully explain the acquisition of migration and invasion, because all of the cell lines should have changed and the R175H did not. It is interesting to note that the R175H cell line had the most differences in expression compared to the other mutant *p53* cell lines (Figure 6B). It may be that other gene changes induced a compensatory mechanism in the R175H cell line or that other changes that are needed to become migratory and invasive were absent in this cell line. Thus, each mutant *p53* may have caused differing levels of migration and invasiveness because each caused a unique spectrum of gene expression changes. Alternatively, mutant *p53* protein may interact with other proteins differently than its wild-type counterpart causing changes in invasive potential. Previous studies with *p53* null human cancer cells exogenously expressing mutant *p53* have shown increased invasion and metastasis in mouse xenograft models [17–19]. Recent studies demonstrated that R273H mutant *p53* can increase migration and invasion of wild-type *p53*-expressing endometrial cancer HHUA cells [42]. Mouse mutant *p53* knock-in models also suggest a role for mutant *p53* in metastasis and invasion [20,21]. These results taken with ours suggest that, even in the presence of wild-type *p53*, certain *p53* mutations can increase cellular invasiveness.

In conclusion, we have developed a novel model system using nonmalignant cells that is in agreement with the previously described functional consequences of mutant *p53* elucidated in malignant cells and extends the increased invasiveness and metastatic potential of *p53* mutant/wild-type heterozygous status found in knock-in mouse models to human mammary epithelial cells. Future studies will be aimed at the elucidation of interactions of mutant *p53* protein with other protein partners and the mechanism of gene expression changes induced by mutant *p53*. This model represents the earliest stages of tumorigenesis and will be useful for determining how *p53* mutation drives the progression of noninvasive primary to metastatic breast cancer in humans to create more effective treatment modalities to block this important, early step in tumorigenesis.

Acknowledgments

We thank the ARL Division of Biotechnology Cytometry Core Facility for generating the flow cytometry data (<http://cytometry.arl.arizona.edu>).

References

- [1] Vogelstein B, Lane D, and Levine AJ (2000). Surfing the *p53* network. *Nature* **408**, 307–310.
- [2] Chen LC, Neubauer A, Kurisu W, Waldman FM, Ljung BM, Goodson W III, Goldman ES, Moore D II, Balazs M, Liu E, et al. (1991). Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. *Proc Natl Acad Sci USA* **88**, 3847–3851.
- [3] Chen YH, Li CD, Yap EP, and McGee JO (1995). Detection of loss of heterozygosity of *p53* gene in paraffin-embedded breast cancers by non-isotopic PCR-SSCP. *J Pathol* **177**, 129–134.
- [4] Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, Chew K, and Smith HS (1994). Loss of heterozygosity and *p53* gene mutations in breast cancer. *Cancer Res* **54**, 499–505.
- [5] Singh S, Simon M, Meybohm I, Jantke I, Jonat W, Maass H, and Goedde HW (1993). Human breast cancer: frequent *p53* allele loss and protein overexpression. *Hum Genet* **90**, 635–640.
- [6] Elledge RM and Allred DC (1994). The *p53* tumor suppressor gene in breast cancer. *Breast Cancer Res Treat* **32**, 39–47.
- [7] Iacopetta B, Grieco F, Powell B, Soong R, McCaul K, and Seshadri R (1998). Analysis of *p53* gene mutation by polymerase chain reaction–single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. *Clin Cancer Res* **4**, 1597–1602.
- [8] Runnebaum IB, Nagarajan M, Bowman M, Soto D, and Sukumar S (1991). Mutations in *p53* as potential molecular markers for human breast cancer. *Proc Natl Acad Sci USA* **88**, 10657–10661.
- [9] Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, and Bergh J (1996). The *p53* gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. *J Natl Cancer Inst* **88**, 173–182.
- [10] Kern SE, Kinzler KW, Baker SJ, Nigro JM, Rotter V, Levine AJ, Friedman P, Privet C, and Vogelstein B (1991). Mutant *p53* proteins bind DNA abnormally *in vitro*. *Oncogene* **6**, 131–136.
- [11] Steinmeyer K and Deppert W (1988). DNA binding properties of murine *p53*. *Oncogene* **3**, 501–507.
- [12] Willis A, Jung EJ, Wakefield T, and Chen X (2004). Mutant *p53* exerts a dominant negative effect by preventing wild-type *p53* from binding to the promoter of its target genes. *Oncogene* **23**, 2330–2338.
- [13] O'Farrell TJ, Ghosh P, Dobashi N, Sasaki CY, and Longo DL (2004). Comparison of the effect of mutant and wild-type *p53* on global gene expression. *Cancer Res* **64**, 8199–8207.
- [14] Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF, Deb SP, and Deb S (2004). Modulation of gene expression by tumor-derived *p53* mutants. *Cancer Res* **64**, 7447–7454.
- [15] Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, Desprez PY, Kung HJ, and deVere White RW (2005). Profiling of gene expression changes caused by *p53* gain-of-function mutant alleles in prostate cancer cells. *Prostate* **65**, 375–389.
- [16] Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, and Rotter V (2004). Transactivation of the *EGFR* gene contributes to mutant *p53* gain of function. *Cancer Res* **64**, 8318–8327.
- [17] Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, and Levine AJ (1993). Gain of function mutations in *p53*. *Nat Genet* **4**, 42–46.
- [18] Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, and Haas M (1994). Gain-of-function mutations of the *p53* gene induce lymphohematopoietic metastatic potential and tissue invasiveness. *Am J Pathol* **145**, 702–714.
- [19] Shaulsky G, Goldfinger N, and Rotter V (1991). Alterations in tumor development *in vivo* mediated by expression of wild type or mutant *p53* proteins. *Cancer Res* **51**, 5232–5237.
- [20] Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, et al. (2004). Gain of function of a *p53* hot spot mutation in a mouse model of Li-Fraumeni syndrome. *Cell* **119**, 861–872.
- [21] Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, and Jacks T (2004). Mutant *p53* gain of function in two mouse models of Li-Fraumeni syndrome. *Cell* **119**, 847–860.
- [22] Stampfer MR and Yaswen P (2000). Culture models of human mammary epithelial cell transformation. *J Mammary Gland Biol Neoplasia* **5**, 365–378.
- [23] Stampfer MR and Yaswen P (2003). Human epithelial cell immortalization as a step in carcinogenesis. *Cancer Lett* **194**, 199–208.
- [24] Yaswen P and Stampfer MR (2002). Molecular changes accompanying senescence and immortalization of cultured human mammary epithelial cells. *Int J Biochem Cell Biol* **34**, 1382–1394.
- [25] Stampfer MR, Garbe J, Levine G, Lichtsteiner S, Vasserot AP, and Yaswen P (2001). Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(–) human mammary epithelial cells. *Proc Natl Acad Sci USA* **98**, 4498–4503.
- [26] Li Y, Pan J, Li JL, Lee JH, Tunkey C, Saraf K, Garbe JC, Whitley MZ, Jelinsky SA, Stampfer MR, et al. (2007). Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. *Mol Cancer* **6**, 7.
- [27] Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, and Yaswen P (2001). The *ZNF217* gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. *Cancer Res* **61**, 1250–1254.
- [28] Rao K, Alper O, Opheim KE, Bonnet G, Wolfe K, Bryant E, O'Hara Larivee S, Porter P, and McDougall JK (2006). Cytogenetic characterization and H-*ras* associated transformation of immortalized human mammary epithelial cells. *Cancer Cell Int* **6**, 15.

- [29] Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Domann FE, and Futscher BW (2003). Mutant *p53* and aberrant cytosine methylation cooperate to silence gene expression. *Oncogene* **22**, 3624–3634.
- [30] Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, et al. (2004). Control of pancreas and liver gene expression by HNF transcription factors. *Science* **303**, 1378–1381.
- [31] Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, and Futscher BW (2007). 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. *Oncogene* **26**, 77–90.
- [32] Smyth GK (2005). Limma: linear models for microarray data. In R Gentleman, S Dudoit, R Irizarry, and W Huber (Eds.), *Bioinformatics and Computational Biology Solutions Using R and Bioconductor*. Springer, New York, pp. 397–420.
- [33] He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, and Vogelstein B (1998). A simplified system for generating recombinant adenoviruses. *Proc Natl Acad Sci USA* **95**, 2509–2514.
- [34] Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ, and McDonnell TJ (2006). Identification of cell cycle regulatory genes as principal targets of *p53*-mediated transcriptional repression. *J Biol Chem* **281**, 25134–25142.
- [35] Milner J and Medcalf EA (1991). Cotranslation of activated mutant *p53* with wild type drives the wild-type *p53* protein into the mutant conformation. *Cell* **65**, 765–774.
- [36] Chicas A, Molina P, and Bargonetti J (2000). Mutant *p53* forms a complex with *Sp1* on HIV-LTR DNA. *Biochem Biophys Res Commun* **279**, 383–390.
- [37] Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, and Piaggio G (2006). Gain of function of mutant *p53*: the mutant *p53*/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. *Cancer Cell* **10**, 191–202.
- [38] Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, and Schuetz JD (2001). Mutant *p53* cooperates with *ETS* and selectively up-regulates human *MDR1* not *MRP1*. *J Biol Chem* **276**, 39359–39367.
- [39] Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, and Goggins M (2005). Epigenetic inactivation of *TFPI-2* as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. *Oncogene* **24**, 850–858.
- [40] Varga AE, Stourman NV, Zheng Q, Safina AF, Quan L, Li X, Sossey-Alaoui K, and Bakin AV (2005). Silencing of the *Tropomyosin-1* gene by DNA methylation alters tumor suppressor function of TGF-beta. *Oncogene* **24**, 5043–5052.
- [41] Gruber AD and Pauli BU (1999). Tumorigenicity of human breast cancer is associated with loss of the Ca²⁺-activated chloride channel *CLCA2*. *Cancer Res* **59**, 5488–5491.
- [42] Dong P, Tada M, Hamada JI, Nakamura A, Moriuchi T, and Sakuragi N (2007). *p53* dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. *Clin Exp Metastasis* **24**, 471–483.